# A Phase 1b Open Label, Dose Escalation Study of PLX3397 in Combination With Vemurafenib in V600-mutated BRAF Melanoma

> **NCT01826448** · PHASE1 · TERMINATED · sponsor: **Daiichi Sankyo** · enrollment: 13 (actual)

## Conditions studied

- V600-mutated BRAF Unresectable Melanoma
- V600-mutated BRAF Metastatic Melanoma
- Stage III or Stage IV Metastatic Melanoma That Has Not Been Previously Treated With a Selective BRAF Inhibitor

## Interventions

- **DRUG:** PLX3397
- **DRUG:** vemurafenib

## Key facts

- **NCT ID:** NCT01826448
- **Lead sponsor:** Daiichi Sankyo
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2013-11-05
- **Primary completion:** 2014-09-22
- **Final completion:** 2014-09-22
- **Target enrollment:** 13 (ACTUAL)
- **Why stopped:** No activity was observed. BRAFi-naïve participants should have received triple combination treatment (including MEK inhibitor). Continuation was not justified.
- **Last updated:** 2020-05-28

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01826448

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01826448, "A Phase 1b Open Label, Dose Escalation Study of PLX3397 in Combination With Vemurafenib in V600-mutated BRAF Melanoma". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT01826448. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*